Cenix takes on second project for CellCentric

Cenix BioScience GmbH, a German specialist in advanced RNA interference-based research services, says that it has initiated a second target validation project under the framework research agreement signed previously with UK-based CellCentric, a biotechnology firm developing therapeutics against a series of novel epigenetic targets.

The new project follows the success of the parties' initial pilot trial, where candidate drug targets chosen by CellCentric for their high therapeutic anticancer potential, were subjected by Cenix to RNAi-based phenotypic characterization using multi-parametric microscopy assays in a diverse panel of human cell lines.

Cenix will now apply the same combination of high throughput RNAi with its own proprietary high content assays using the Definiens Cellenger image analysis platform, to generate a detailed characterization of loss-of-function phenotypes for several more oncology target candidates across a new collection of human cell lines.